Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling